Boston Scientific Corporation has launched the Promus PREMIER Everolimus-Eluting Platinum Chromium Coronary Stent System in Japan. This advanced DES system recently received Japan Ministry of Health, Labor and Welfare (MHLW) approval.
"It is my great pleasure to be able to provide the Promus PREMIER Stent System to physicians and patients in Japan," said Yusuke Naiki, president and representative director for Boston Scientific Japan K.K. "This innovative stent enhances our portfolio of coronary intervention products, and we believe it will strengthen our position in Japan's DES market."
Coronary artery disease is a narrowing of blood vessels that supply blood and oxygen to the heart. Patients with coronary artery disease may experience pain, shortness of breath and fatigue. They may also be at risk for a heart attack. One treatment option is the placement of a stent in the artery to help keep it open and allow the blood to flow more freely.
The Promus PREMIER Stent System was developed with extensive input from interventional cardiologists and is designed to provide best-in-class acute performance and clinical outcomes. It features unparalleled visibility and low recoil, plus exceptional radial strength and fracture resistance. An enhanced low-profile delivery system is designed to facilitate precise stent delivery across challenging lesions.
"The Promus PREMIER Stent System reflects our commitment to DES technology and to providing interventional cardiologists with the most complete portfolio of clinical solutions," said Kevin Ballinger, president, Interventional Cardiology, Boston Scientific. "Japan is an important interventional cardiology market, and we believe the launch and success of this stent system in Japan will enhance Boston Scientific's overall growth strategy in the DES market."
The Promus PREMIER Stent System received CE Mark and FDA approvals in February and November of 2013, respectively.